Tecentriq approved for first-line metastatic NSCLC

Roche’s checkpoint inhibitor Tecentriq has gained a new approval from the European Commission, for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC), its fourth indication in this cancer type.